Back to Results

EnVVeno Medical Corp (NVNO)

enVVeno Medical Corp is a clinical-stage medical device company listed on NASDAQ under the ticker NVNO. The company develops bioprosthetic, tissue-based solutions aimed at improving treatment options for venous disease. Its lead program is VenoValve, a replacement venous valve designed for patients with chronic venous insufficiency and implanted through an open surgical procedure in the femoral vein. enVVeno Medical is also working on enVVe, a non-surgical, transcatheter-based venous valve system that includes the valve, delivery system, and related accessories. Founded in 1999 and based in Irvine, California, the company was previously known as Hancock Jaffe Laboratories, Inc. before adopting its current name in October 2021.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-NVNO
$14.44
33.8% Upside
Undervalued
$30
178.0% Upside
Bargain
Fair
—
—
—
0.0%
August 5, 2026
-0.4x
0.3x
—
7.364 M
-17.123 M
7.6%
72.8%
-7.3
—
78.6%
Valuation • Fair Value

enVVeno Medical Corp (NASDAQ-NVNO) Fair Value by Valuation Model

Compare the primary fair value estimate for enVVeno Medical Corp (NASDAQ-NVNO) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$14.44

Estimated upside of 33.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$14.44

Comparable-company valuation reference.

Analyst Price Target

$30

Analysts imply upside of 178.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for enVVeno Medical Corp (NASDAQ-NVNO) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for enVVeno Medical Corp (NASDAQ-NVNO)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-19.88 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review enVVeno Medical Corp (NASDAQ-NVNO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for enVVeno Medical Corp (NASDAQ-NVNO)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-7.3

Lower score that deserves closer risk review.

FCF / Net Income

78.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for enVVeno Medical Corp (NASDAQ-NVNO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for enVVeno Medical Corp (NASDAQ-NVNO)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for enVVeno Medical Corp (NASDAQ-NVNO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

enVVeno Medical Corp (NASDAQ-NVNO) Stock Forecast & Technical Outlook

Review enVVeno Medical Corp (NASDAQ-NVNO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for enVVeno Medical Corp (NASDAQ-NVNO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for enVVeno Medical Corp (NASDAQ-NVNO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for enVVeno Medical Corp (NASDAQ-NVNO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for enVVeno Medical Corp (NASDAQ-NVNO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for enVVeno Medical Corp (NASDAQ-NVNO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for enVVeno Medical Corp (NASDAQ-NVNO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, enVVeno Medical Corp (NASDAQ-NVNO) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

enVVeno Medical Corp (NASDAQ-NVNO) Stock FAQ

Quick answers about enVVeno Medical Corp (NASDAQ-NVNO) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$14.44
Estimated upside 33.8%
Valuation Rating
Undervalued
Estimated upside of 33.8%
Analyst Target
$30
Implied upside 178.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for enVVeno Medical Corp (NASDAQ-NVNO) is $14.44. This implies an estimated upside of 33.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 33.8% versus the current market price.

The available analyst price target for enVVeno Medical Corp (NASDAQ-NVNO) is $30. The analyst target implies estimated upside of 178.0%.

The current financial health read for enVVeno Medical Corp (NASDAQ-NVNO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for enVVeno Medical Corp (NASDAQ-NVNO) is August 5, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for enVVeno Medical Corp (NASDAQ-NVNO) is -0.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for enVVeno Medical Corp is 7.364 M.

The current enterprise value listed for enVVeno Medical Corp is -17.123 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for enVVeno Medical Corp is NASDAQ-NVNO, and the stock is listed on NASDAQ.

enVVeno Medical Corp (NASDAQ-NVNO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for enVVeno Medical Corp is 7.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for enVVeno Medical Corp is 72.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NASDAQ View more

Intuitive Surgical Inc (ISRG) Intuitive Surgical Inc (ISRG)
Medline Inc (MDLN) Medline Inc (MDLN)
IDEXX Laboratories Inc (IDXX) IDEXX Laboratories Inc (IDXX)
DexCom Inc (DXCM) DexCom Inc (DXCM)
GE HealthCare Technologies Inc (GEHC) GE HealthCare Technologies Inc (GEHC)
Cooper Companies Inc (COO) Cooper Companies Inc (COO)
Align Technology Inc (ALGN) Align Technology Inc (ALGN)
Insulet Corporation (PODD) Insulet Corporation (PODD)
Lantheus Holdings Inc (LNTH) Lantheus Holdings Inc (LNTH)
MiniMed Group Inc (MMED) MiniMed Group Inc (MMED)
Merit Medical Systems Inc (MMSI) Merit Medical Systems Inc (MMSI)
LivaNova PLC (LIVN) LivaNova PLC (LIVN)
ICU Medical Inc (ICUI) ICU Medical Inc (ICUI)
IRhythm Technologies Inc (IRTC) IRhythm Technologies Inc (IRTC)
Establishment Labs Holdings Inc (ESTA) Establishment Labs Holdings Inc (ESTA)
Dentsply Sirona Inc (XRAY) Dentsply Sirona Inc (XRAY)
TransMedics Group Inc (TMDX) TransMedics Group Inc (TMDX)
LeMaitre Vascular Inc (LMAT) LeMaitre Vascular Inc (LMAT)
Neogen Corporation (NEOG) Neogen Corporation (NEOG)
Axogen Inc (AXGN) Axogen Inc (AXGN)
Omnicell Inc (OMCL) Omnicell Inc (OMCL)
Pulse Biosciences Inc (PLSE) Pulse Biosciences Inc (PLSE)
UFP Technologies Inc (UFPT) UFP Technologies Inc (UFPT)
Novocure Ltd (NVCR) Novocure Ltd (NVCR)